Terry Pearson
Director Técnico/Científico/I+D en Siscapa Assay Technologies, Inc. .
Perfil
Terry W.
Pearson is currently serving as a Director at CAVA Healthcare, Inc., Director at Science Council of British Columbia, Director at Eyam Vaccines & Immunotherapeutics Ltd., and Chief Scientific Officer at Siscapa Assay Technologies, Inc. Previously, he held positions as a Director at Marker Therapeutics, Inc., Independent Director at biOasis Technologies, Inc., Independent Director at Nevis Brands, Inc., Staff Scientist-Cell Biology Division at the University of British Columbia, Professor at the University of Victoria, and Trustee at The Terry Fox Foundation.
He obtained his undergraduate and doctorate degrees from the University of British Columbia.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
inf% | 18/10/2023 | 100 000 ( inf% ) | - $ | Hoy |
Cargos activos de Terry Pearson
| Empresas | Cargo | Inicio |
|---|---|---|
| Science Council of British Columbia | Director/Miembro de la Junta | 01/09/2010 |
CAVA Healthcare, Inc.
 CAVA Healthcare, Inc. Food: Specialty/CandyConsumer Non-Durables CAVA Healthcare, Inc. operates as a early stage biotechnology company. The company is headquartered in Surrey, Canada. | Director/Miembro de la Junta | - |
Siscapa Assay Technologies, Inc.
 Siscapa Assay Technologies, Inc. BiotechnologyHealth Technology Siscapa Assay Technologies, Inc. provides products and services for precise quantitation of protein biomarkers, drugs, and drug targets using immuno-affinity mass spectrometry. Siscapa assays are used in clinical diagnostics and pharma R&D for particularly demanding applications, and in biomarker panels to characterize changes in health, disease, and treatment in longitudinal user-collected dried blood microsamples. Siscapa immuno-affinity mass spectrometry assays for targeted protein quantitation can be developed more quickly than typical ELISA immunoassays since they require only a single specific antibody and provide absolute target specificity because of the MS detection. Because Siscapa assays do not interact with one another, these assays can be freely assembled in panels for various applications. The American company was founded by N. Leigh Anderson, who has been the CEO since incorporation. | Director Técnico/Científico/I+D | - |
| Eyam Vaccines & Immunotherapeutics Ltd. | Director/Miembro de la Junta | 10/01/2022 |
Antiguos cargos conocidos de Terry Pearson.
| Empresas | Cargo | Fin |
|---|---|---|
| BIOASIS TECHNOLOGIES INC. | Director/Miembro de la Junta | 21/09/2017 |
| MARKER THERAPEUTICS, INC. | Director/Miembro de la Junta | 05/12/2005 |
| University of British Columbia | Corporate Officer/Principal | - |
| NEVIS BRANDS INC. | Director/Miembro de la Junta | - |
| University of Victoria | Corporate Officer/Principal | - |
Formación de Terry Pearson.
| University of British Columbia | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| MARKER THERAPEUTICS, INC. | Health Technology |
| BIOASIS TECHNOLOGIES INC. | Health Technology |
| NEVIS BRANDS INC. | Health Technology |
| Empresas privadas | 5 |
|---|---|
| The Terry Fox Foundation | |
| Science Council of British Columbia | |
CAVA Healthcare, Inc.
CAVA Healthcare, Inc. Food: Specialty/CandyConsumer Non-Durables CAVA Healthcare, Inc. operates as a early stage biotechnology company. The company is headquartered in Surrey, Canada. | Consumer Non-Durables |
Siscapa Assay Technologies, Inc.
Siscapa Assay Technologies, Inc. BiotechnologyHealth Technology Siscapa Assay Technologies, Inc. provides products and services for precise quantitation of protein biomarkers, drugs, and drug targets using immuno-affinity mass spectrometry. Siscapa assays are used in clinical diagnostics and pharma R&D for particularly demanding applications, and in biomarker panels to characterize changes in health, disease, and treatment in longitudinal user-collected dried blood microsamples. Siscapa immuno-affinity mass spectrometry assays for targeted protein quantitation can be developed more quickly than typical ELISA immunoassays since they require only a single specific antibody and provide absolute target specificity because of the MS detection. Because Siscapa assays do not interact with one another, these assays can be freely assembled in panels for various applications. The American company was founded by N. Leigh Anderson, who has been the CEO since incorporation. | Health Technology |
| Eyam Vaccines & Immunotherapeutics Ltd. |
- Bolsa de valores
- Insiders
- Terry Pearson
